NicVAX/Placebo as an Aid for Smoking Cessation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00836199
Recruitment Status : Completed
First Posted : February 4, 2009
Last Update Posted : May 9, 2012
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Nabi Biopharmaceuticals

Brief Summary:
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.

Condition or disease Intervention/treatment Phase
Smoking Cessation Smoking Tobacco Cessation Biological: NicVAX vaccine Biological: Placebo vaccine Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Study Start Date : October 2009
Primary Completion Date : July 2011
Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: Placebo vaccine Biological: Placebo vaccine
Placebo vaccine given 6 times over 6 months
Experimental: NicVAX vaccine Biological: NicVAX vaccine
NicVAX vaccine given 6 times over 6 months

Primary Outcome Measures :
  1. Evaluate NicVAX as an aid to smoking cessation for long term abstinence. [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Evaluate abstinence rates at multiple intervals [ Time Frame: multiple time points ]
  2. Evaluate safety and immunogenicity [ Time Frame: mulitple time points ]
  3. Evaluate withdrawal symptoms, smoking satisfaction, cigarette consumption and nicotine dependence. [ Time Frame: multiple time points ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Current smoker who smokes at least 10 cigarettes a day during the past year and wants to quit smoking.
  • Smokers who are in good general health.

Exclusion Criteria:

  • Prior exposure to NicVAX or any other nicotine vaccine.
  • Use of systemic steroids.
  • Cancer or cancer treatment in last 5 years.
  • HIV infection.
  • History of drug or alcohol abuse or dependence within 12 months.
  • Significant cardiovascular, hepatic, renal, psychiatric and/or respiratory disease.
  • Inability to fulfill all visits for approximately 52 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00836199

  Hide Study Locations
United States, Arizona
NicVAX Investigator
Tucson, Arizona, United States
United States, California
NicVAX Investigator
Los Angeles, California, United States
NicVAX Investigator
Newport Beach, California, United States
NicVAX Investigator
San Diego, California, United States
United States, Colorado
NicVAX Investigator
Denver, Colorado, United States
United States, Connecticut
NicVAX Investigator
Farmington, Connecticut, United States
United States, Florida
NicVAX Investigator
Miami, Florida, United States
NicVAX Investigator
St. Petersburg, Florida, United States
United States, Idaho
NicVAX Investigator
Boise, Idaho, United States
United States, Kentucky
NicVAX Investigator
Lexington, Kentucky, United States
United States, Maryland
NicVAX Investigator
Baltimore, Maryland, United States
NicVAX Investigator
College Park, Maryland, United States
United States, Massachusetts
NicVAX Investigator
Boston, Massachusetts, United States
United States, Minnesota
NicVAX Investigator
Minneapolis, Minnesota, United States
United States, Nebraska
NicVAX Investigator
Omaha, Nebraska, United States
United States, New York
NicVAX Investigator
Rochester, New York, United States
United States, North Carolina
NicVAX Investigator
Raleigh, North Carolina, United States
United States, Oregon
NicVAX Investigator
Portland, Oregon, United States
United States, Utah
NicVAX Investigator
Draper, Utah, United States
United States, Virginia
NicVAX Investigator
Norfolk, Virginia, United States
United States, Washington
NicVAX Investigator
Seattle, Washington, United States
United States, Wisconsin
NicVAX Investigator
Madison, Wisconsin, United States
Sponsors and Collaborators
Nabi Biopharmaceuticals
National Institute on Drug Abuse (NIDA)
Study Director: Medical Monitor Nabi Biopharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nabi Biopharmaceuticals Identifier: NCT00836199     History of Changes
Other Study ID Numbers: Nabi-4514
NIH grant # 1 RC2 DA028837-01
First Posted: February 4, 2009    Key Record Dates
Last Update Posted: May 9, 2012
Last Verified: May 2012

Keywords provided by Nabi Biopharmaceuticals:
smoking cessation
smoking vaccine
smoking abstinence
tobacco cessation

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs